All Stories

  1. Indolyl Azaspiroketal Mannich Bases Are Potent Antimycobacterial Agents with Selective Membrane Permeabilizing Effects and in Vivo Activity
  2. Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis
  3. 1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity
  4. Whole-Cell Screen of Fragment Library Identifies Gut Microbiota Metabolite Indole Propionic Acid as Antitubercular
  5. Pyrazinoic Acid Inhibits Mycobacterial Coenzyme A Biosynthesis by Binding to Aspartate Decarboxylase PanD
  6. Indolylalkyltriphenylphosphonium Analogues Are Membrane-Depolarizing Mycobactericidal Agents
  7. Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
  8. Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates
  9. Draft Genome Sequence of Mycobacterium avium 11
  10. Draft Genome Sequence of Mycobacterium abscessus Bamboo
  11. The uniqueness of subunit α of mycobacterial F-ATP synthases: An evolutionary variant for niche adaptation
  12. Bortezomib Warhead-Switch Confers Dual Activity against Mycobacterial Caseinolytic Protease and Proteasome and Selectivity against Human Proteasome
  13. Rifabutin Is Active against Mycobacterium abscessus Complex
  14. Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure–Activity Relationships and Membrane Targeting Properties
  15. In Vivo-Selected Pyrazinoic Acid-Resistant Mycobacterium tuberculosis Strains Harbor Missense Mutations in the Aspartate Decarboxylase PanD and the Unfoldase ClpC1
  16. Mycobacterial Caseinolytic Protease Gene Regulator ClgR Is a Substrate of Caseinolytic Protease
  17. Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome
  18. Missense Mutations in the Unfoldase ClpC1 of the Caseinolytic Protease Complex Are Associated with Pyrazinamide Resistance in Mycobacterium tuberculosis
  19. Amphiphilic xanthones as a potent chemical entity of anti-mycobacterial agents with membrane-targeting properties
  20. Developmental transcriptome of resting cell formation in Mycobacterium smegmatis
  21. Bedaquiline Targets the ε Subunit of Mycobacterial F-ATP Synthase
  22. Fragment-Based Whole Cell Screen Delivers Hits against M. tuberculosis and Non-tuberculous Mycobacteria
  23. Rel Is Required for Morphogenesis of Resting Cells in Mycobacterium smegmatis
  24. Pyrazinamide Resistance Is Caused by Two Distinct Mechanisms: Prevention of Coenzyme A Depletion and Loss of Virulence Factor Synthesis
  25. Mild Nutrient Starvation Triggers the Development of a Small-Cell Survival Morphotype in Mycobacteria
  26. Membrane-targeting AM-0016 kills mycobacterial persisters and shows low propensity for resistance development
  27. Deletion of a unique loop in the mycobacterial F-ATP synthase γ subunit sheds light on its inhibitory role in ATP hydrolysis-driven H+pumping
  28. Boromycin Kills Mycobacterial Persisters without Detectable Resistance
  29. Eagle Effect in Nonreplicating Persister Mycobacteria
  30. Target Mechanism-Based Whole-Cell Screening Identifies Bortezomib as an Inhibitor of Caseinolytic Protease in Mycobacteria
  31. Metabolic flexibility and morphological plasticity in mycobacteria
  32. The new tuberculosis drug Perchlozone® shows cross-resistance with thiacetazone
  33. Antibacterial Drug Discovery: Doing It Right
  34. Future target-based drug discovery for tuberculosis?
  35. Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents
  36. Reactive dirty fragments: implications for tuberculosis drug discovery
  37. Pharmacokinetics-Pharmacodynamics Analysis of Bicyclic 4-Nitroimidazole Analogs in a Murine Model of Tuberculosis
  38. Corrrection to Discovery of Tetrahydropyrazolopyrimidine Carboxamide Derivatives As Potent and Orally Active Novel Antitubercular Agents
  39. Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis
  40. Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides: A Promising Class of Antituberculosis Agents
  41. Correction: Characterization of Phosphofructokinase Activity in Mycobacterium tuberculosis Reveals That a Functional Glycolytic Carbon Flow Is Necessary to Limit the Accumulation of Toxic Metabolic Intermediates under Hypoxia
  42. para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis.
  43. Exploring the Mode of Action of Bioactive Compounds by Microfluidic Transcriptional Profiling in Mycobacteria
  44. In silico analyses for the discovery of tuberculosis drug targets
  45. para-Aminosalicylic Acid Is a Prodrug Targeting Dihydrofolate Reductase in Mycobacterium tuberculosis
  46. Discovery of Tetrahydropyrazolopyrimidine Carboxamide Derivatives As Potent and Orally Active Antitubercular Agents
  47. Characterization of Phosphofructokinase Activity in Mycobacterium tuberculosis Reveals That a Functional Glycolytic Carbon Flow Is Necessary to Limit the Accumulation of Toxic Metabolic Intermediates under Hypoxia
  48. Reduced Drug Uptake in Phenotypically Resistant Nutrient-Starved Nonreplicating Mycobacterium tuberculosis
  49. Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824
  50. A novel F 420 ‐dependent anti‐oxidant mechanism protects M ycobacterium tuberculosis against oxidative stress and bacter...
  51. Heterogeneity of Mycobacterium tuberculosis strains in Makassar, Indonesia
  52. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis
  53. Detection and treatment of subclinical tuberculosis
  54. Variations of Subunit ε of the Mycobacterium tuberculosis F1FoATP Synthase and a Novel Model for Mechanism of Action of the Tuberculosis Drug TMC207
  55. A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating Mycobacterium tuberculosis
  56. HowMycobacterium tuberculosisgoes to sleep: the dormancy survival regulator DosR a decade later
  57. Structure of Ddn, the Deazaflavin-Dependent Nitroreductase from Mycobacterium tuberculosis Involved in Bioreductive Activation of PA-824
  58. Chapter 14. Natural Products: New Agents Against MDR Tuberculosis
  59. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles
  60. Structure–Activity Relationships of Antitubercular Nitroimidazoles. 3. Exploration of the Linker and Lipophilic Tail of ((S)-2-Nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-Amino PA-824).
  61. How antibacterials really work: impact on drug discovery
  62. Drug resistance among tuberculosis patients attending diagnostic and treatment centres in Makassar, Indonesia
  63. Nitrate Respiration Protects Hypoxic Mycobacterium tuberculosis Against Acid- and Reactive Nitrogen Species Stresses
  64. Vitamin B6 biosynthesis is essential for survival and virulence of Mycobacterium tuberculosis
  65. Tuberculosis Biology and Drug Discovery
  66. A Color Atlas of Comparative Pathology of Pulmonary Tuberculosis
  67. Lipid Droplet-associated Proteins Are Involved in the Biosynthesis and Hydrolysis of Triacylglycerol in Mycobacterium bovis Bacillus Calmette-Guerin
  68. Spectrum of latent tuberculosis — existing tests cannot resolve the underlying phenotypes: author's reply
  69. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
  70. Nutrient-starved, non-replicating Mycobacterium tuberculosis requires respiration, ATP synthase and isocitrate lyase for maintenance of ATP homeostasis and viability
  71. Corrections to Structure−Activity Relationships of Antitubercular Nitroimidazoles. 2. Determinants of Aerobic Activity and Quantitative Structure−Activity Relationships
  72. Triacylglycerol Utilization Is Required for Regrowth of In Vitro Hypoxic Nonreplicating Mycobacterium bovis Bacillus Calmette-Guerin
  73. Structure−Activity Relationships of Antitubercular Nitroimidazoles. 2. Determinants of Aerobic Activity and Quantitative Structure−Activity Relationships
  74. Peptide deformylase inhibitors of Mycobacterium tuberculosis: Synthesis, structural investigations, and biological results
  75. Biochemical and structural characterization of the putative dihydropteroate synthase ortholog Rv1207 of Mycobacterium tuberculosis
  76. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis
  77. Recombinase-based reporter system and antisense technology to study gene expression and essentiality in hypoxic nonreplicating mycobacteria
  78. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis
  79. Sensitive profiling of chemically diverse bioactive lipids
  80. Peptide Deformylase Inhibitors as Potent Antimycobacterial Agents
  81. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis
  82. Role for malonyl coenzyme A:acyl carrier protein transacylase (MCAT) in the growth-inhibitory effect of the calmodulin antagonist trifluoperazine in Mycobacterium bovis BCG
  83. Isoniazid resistance of exponentially growing Mycobacterium smegmatis biofilm culture
  84. Apparent growth phase-dependent phosphorylation of malonyl coenzyme A:acyl carrier protein transacylase (MCAT), a major fatty acid synthase II component in Mycobacterium bovis BCG
  85. Mycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy
  86. In vitro activity of the chelating agents nitroxoline and oxine against Mycobacterium bovis BCG
  87. In Vitro Activities of Mitomycin C against Growing and Hypoxic Dormant Tubercle Bacilli
  88. Plate-based dormancy culture system for Mycobacterium smegmatis and isolation of metronidazole-resistant mutants
  89. Mycobacterium bovis BCG recADeletion Mutant Shows Increased Susceptibility to DNA-Damaging Agents but Wild-Type Survival in a Mouse Infection Model
  90. Plate-based dormancy culture system for Mycobacterium smegmatis and isolation of metronidazole-resistant mutants
  91. Proteins of Mycobacterium bovis BCG Induced in the Wayne Dormancy Model
  92. Dormant tubercle bacilli: the key to more effective TB chemotherapy?
  93. Bacterial and host-derived cationic proteins bind α2-laminins and enhance Mycobacterium leprae attachment to human Schwann cells
  94. Analysis of the dormancy-inducible narK2 promoter in Mycobacterium bovis BCG
  95. Analysis of the dormancy-inducible narK2 promoter in Mycobacterium bovis BCG
  96. Inducibility of the Streptomyces traRts107-Ptra Expression Cassette in Mycobacterium smegmatis
  97. Upregulation of stress response genes and ABC transporters in anaerobic stationary-phase Mycobacterium smegmatis
  98. Up-regulation of narX , encoding a putative ‘fused nitrate reductase’ in anaerobic dormant Mycobacterium bovis BCG
  99. Up-regulation of narX, encoding a putative 'fused nitrate reductase' in anaerobic dormant Mycobacterium bovis BCG
  100. Molecular genetic characterisation of whiB3, a mycobacterial homologue of a Streptomyces sporulation factor
  101. Upregulation of a histone-like protein in dormant Mycobacterium smegmatis
  102. Increased alanine dehydrogenase activity during dormancy in Mycobacterium smegmatis
  103. Increased alanine dehydrogenase activity during dormancy in Mycobacterium smegmatis
  104. Oxygen depletion induced dormancy in Mycobacterium smegmatis
  105. Oxygen depletion induced dormancy in Mycobacterium smegmatis
  106. Drosophila DPP2C1, a novel member of the protein phosphatase 2C (PP2C) family
  107. Cytoplasmic dynein (ddlc1) mutations cause morphogenetic defects and apoptotic cell death in Drosophila melanogaster.
  108. Molecular and genetic characterization ofSLC1, a putativeSaccharomyces cerevisiae homolog of the metazoan cytoplasmic dynein light chain 1
  109. Molecular characterization of the Drosophila homologue of the human serine/threonine protein phosphatase 2C
  110. On the functional overlap between two Drosophila POU homeo domain genes and the cell fate specification of a CNS neural precursor.
  111. The role of a Drosophila POU homeo domain gene in the specification of neural precursor cell identity in the developing embryonic central nervous system.
  112. Two closely linked Drosophila POU domain genes are expressed in neuroblasts and sensory elements.
  113. Chloramphenicol-induced translational activation of cat messenger RNA in vitro
  114. Positioning ribosomes on leader mRNA for translational activation of the message of an inducible Staphylococcus aureus cat gene
  115. REGULATION OF INDUCIBLE STAPHYLOCOCCUS AUREUS CAT GENE BY TRANSLATIONAL ATTENUATION
  116. Dependence of expression of an inducible Staphylococcus aureus cat gene on the translation of its leader sequence
  117. Tuberculosis Drug Discovery: Issues, Gaps and the Way Forward